PCSK9与动脉粥样硬化的研究进展  

Research progress of PCSK9 and atherosclerosis

作　　者：逯朝阳 姚瑶[1,2] 郭春玲(综述)[1,2] 杨滨 李保(审校) LU Zhao-yang;YAO Yao;GUO Chun-ling;YANG Bin;LI Bao(Department of Cardiology,the Second Hospital of Shanxi Medical University,Taiyuan 030013,Shanxi,CHINA;Shanxi Medical University,Taiyuan 030001,Shanxi,CHINA)

机构地区：[1]山西医科大学第二医院心血管内科,山西太原030013 [2]山西医科大学,山西太原030001

出　　处：《海南医学》2022年第4期504-508,共5页Hainan Medical Journal

基　　金：国家自然科学基金青年科学基金项目(编号:81900275);山西省科技厅面上项目(编号:201801D221273);山西省卫生健康委员会科研项目(编号:2017053)。

摘　　要：动脉粥样硬化是一种累及动脉壁的炎症性疾病,其主要特征是脂质和炎症细胞在大动脉内膜下聚积。前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂目前是临床上常用的降血脂药之一,虽然临床试验已证实PCSK9是降低血脂和预防及治疗动脉粥样硬化进展的生物靶点,但其生理作用尚未被完全阐明。目前多项证据表明,PCSK9可以通过调控脂蛋白代谢紊乱和炎症相关的机制促进动脉粥样硬化疾病的发生发展。本文对近年来PCSK9与动脉粥样硬化疾病的研究进展及PCSK9抑制剂在临床上的应用进行了综述。Atherosclerosis is an inflammatory disease that affects the arterial wall,characterized by the accumulation of lipids and inflammatory cells under the inner lining of the aorta.At present,the proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitor is one of the commonly used hypolipidemic drugs in clinical practice.Although clinical trials have confirmed that PCSK9 is a biological target for reducing blood lipids and preventing and treating the progression of atherosclerosis,its physiological role has not been fully elucidated.Currently,there is a lot of evidence to suggest that PCSK9 can promote the occurrence and development of atherosclerosis by regulating lipoprotein metabolism disorders and inflammation-related mechanisms.This article reviews the research progress of PCSK9 and atherosclerosis in recent years as well as the clinical application of PCSK9 inhibitors.

关 键 词：前蛋白转化酶枯草溶菌素9 低密度脂蛋白胆固醇 炎症 动脉粥样硬化 心血管疾病 

分 类 号：R541.4[医药卫生—心血管疾病]